📊 BCRX Key Takeaways
Investment Thesis
BioCryst demonstrates exceptional revenue growth (+94.1% YoY) and strong profitability metrics (39% operating margin, 30.2% net margin) with robust free cash flow generation ($344.9M). However, the negative stockholders' equity of -$119.2M represents a critical balance sheet deterioration that must be resolved, creating meaningful financial risk despite operational strength.
BCRX Strengths
- Exceptional revenue growth of 94.1% year-over-year indicating strong market demand
- Impressive net income growth of 396.9% with net margin of 30.2% showing operational leverage
- Strong free cash flow generation at $344.9M (39.4% FCF margin) providing financial flexibility
- Healthy liquidity position with current ratio of 2.06x and quick ratio of 2.03x
- Robust operating cash flow of $347.4M with minimal capital expenditure requirements
BCRX Risks
- Critical balance sheet weakness with negative stockholders' equity of -$119.2M indicating liabilities exceed assets by $119.2M
- Total liabilities of $633.3M exceed total assets of $514.2M, creating solvency concerns
- Significant insider trading activity with 10 Form 4 filings in last 90 days warrants monitoring for insider confidence signals
- Negative equity makes traditional leverage metrics meaningless and limits financing flexibility
- Sustainability of 94% revenue growth rates uncertain; margin compression risk if growth moderates
Key Metrics to Watch
- Stockholders' equity trajectory and debt reduction plan to return to positive equity position
- Revenue growth sustainability and gross margin trends as company scales
- Free cash flow generation capability and deployment strategy to strengthen balance sheet
- Operating leverage and net margin sustainability at current profitability levels
- Insider transaction patterns and management commentary on balance sheet restoration
BCRX Financial Metrics
💡 AI Analyst Insight
The 39.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.06x current ratio provides a solid financial cushion.
BCRX Profitability Ratios
BCRX vs Healthcare Sector
How BIOCRYST PHARMACEUTICALS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BCRX Balance Sheet & Liquidity
BCRX 5-Year Financial Trend
5-Year Trend Summary: BIOCRYST PHARMACEUTICALS INC's revenue has grown significantly by 457% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.18 indicates the company is currently unprofitable.
BCRX Growth Metrics (YoY)
BCRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $117.1M | $32.0K | $0.06 |
| Q2 2025 | $109.3M | $32.0K | $0.02 |
| Q1 2025 | $92.8M | $32.0K | $0.00 |
| Q3 2024 | $86.7M | -$12.7M | $-0.07 |
| Q2 2024 | $82.5M | -$12.7M | $-0.06 |
| Q1 2024 | $68.8M | -$35.4M | $-0.17 |
| Q3 2023 | $75.8M | -$36.1M | $-0.19 |
| Q2 2023 | $65.5M | -$53.3M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BCRX Capital Allocation
BCRX SEC Filings
Access official SEC EDGAR filings for BIOCRYST PHARMACEUTICALS INC (CIK: 0000882796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCRX
What is the AI rating for BCRX?
BIOCRYST PHARMACEUTICALS INC (BCRX) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCRX's key strengths?
Exceptional revenue growth of 94.1% year-over-year indicating strong market demand. Impressive net income growth of 396.9% with net margin of 30.2% showing operational leverage.
What are the risks of investing in BCRX?
Critical balance sheet weakness with negative stockholders' equity of -$119.2M indicating liabilities exceed assets by $119.2M. Total liabilities of $633.3M exceed total assets of $514.2M, creating solvency concerns.
What is BCRX's revenue and growth?
BIOCRYST PHARMACEUTICALS INC reported revenue of $874.8M.
Does BCRX pay dividends?
BIOCRYST PHARMACEUTICALS INC does not currently pay dividends.
Where can I find BCRX SEC filings?
Official SEC filings for BIOCRYST PHARMACEUTICALS INC (CIK: 0000882796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCRX's EPS?
BIOCRYST PHARMACEUTICALS INC has a diluted EPS of $1.21.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.